| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
| ln Vitro |
Thiostrepton (0.01-1000 μM; 48 hours) suppresses cell viability in A2780 and HEC-1A[2].
|
|---|---|
| ln Vivo |
Thiostrepton (i.p. ; 17 mg/kg) decreases Ewing's sarcoma (EWS) cell carcinogenicity. The tumor volumes of control mice have increased approximately six times since the start of treatment, whereas the tumor volumes of mice treated with Thiostrepton have increased only approximately 1.7 times, showing a ~3.5-fold reduction, in comparison to controls[3].
|
| Cell Assay |
Cell Line: A2780 and HEC-1A cells
Concentration: 0.01, 0.1, 1, 10, 100, 1000 μM Incubation Time: 48 hours Result: The IC50s are 1.10 μM in A2780 and 2.22 μM in HEC-1A, respectively. |
| Animal Protocol |
Animal Model: Athymic (BALB/c nu/nu) nude mice bearing A4573 cells[3]
Dosage: 17 mg/kg Administration: Administered i.p. Result: Treatment inhibited the growth of EWS-derived tumors in vivo. |
| References |
|
| Additional Infomation |
Thiostrepton is a natural cyclic oligopeptide antibiotic, derived from several strains of streptomycetes including Streptomyces azureus and Streptomyces laurentii. Thiostrepton is a natural product of the ribosomally synthesized and post-translationally modified peptide class.
Bryamycin has been reported in Streptomyces albidoflavus, Streptomyces aureus, and other organisms with data available. Thiostrepton is a naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class, and an irreversible inhibitor of the mitochondrial thioredoxin-dependent peroxide reductase (peroxiredoxin-3; PRX3; antioxidant protein 1; AOP-1), with potential antineoplastic activity. Upon intrapleural administration, thiostrepton irreversibly binds to and inhibits the activity of PRX3. This inhibits the peroxidase activity of the thioredoxin reductase 2 (TXNRD2)-thioredoxin-2 (TRX2)-PRX3 antioxidant signaling network within the mitochondria, which may result in the accumulation of hydrogen peroxide and lead to tumor cell death. PRX3 is upregulated in cancer cells and plays an important role in the regulation of the oxidative stress pathways. One of the CYCLIC PEPTIDES from Streptomyces that is active against gram-positive bacteria. In veterinary medicine, it has been used in mastitis caused by gram-negative organisms and in dermatologic disorders. See also: Thiostrepton (annotation moved to). |
| Molecular Formula |
C72H85N19O18S5
|
|---|---|
| Molecular Weight |
1664.89
|
| Exact Mass |
1663.49
|
| Elemental Analysis |
C, 51.94; H, 5.15; N, 15.99; O, 17.30; S, 9.63
|
| CAS # |
1393-48-2
|
| PubChem CID |
16129666
|
| Appearance |
White to off-white solid powder
|
| Density |
1.64 g/cm3
|
| Melting Point |
248-257°C (dec.)
|
| Index of Refraction |
1.768
|
| LogP |
4.086
|
| Hydrogen Bond Donor Count |
17
|
| Hydrogen Bond Acceptor Count |
31
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
114
|
| Complexity |
3940
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C([H])=C2C(N([H])C([H])(C(N([H])C(=C([H])C([H])([H])[H])C3=NC([H])(C([H])([H])S3)C(N([H])C([H])(C3=NC(=C([H])S3)C(N([H])C3([H])C([H])(C([H])([H])[H])OC(C4C([H])=C(C([H])(C([H])([H])[H])O[H])C5C([H])=C([H])C([H])(C([H])(C=5N=4)O[H])N([H])C([H])(C(N([H])C([H])(C([H])([H])[H])C(N([H])C(=C([H])[H])C(N([H])C([H])(C([H])([H])[H])C(N([H])C4(C1=N2)C([H])([H])C([H])([H])C(C1=NC(C(N([H])C(=C([H])[H])C(N([H])C(=C([H])[H])C(N([H])[H])=O)=O)=O)=C([H])S1)=NC4([H])C1=C([H])SC3=N1)=O)=O)=O)=O)C([H])(C([H])([H])[H])C([H])([H])C([H])([H])[H])=O)=O)C(C([H])([H])[H])(C([H])(C([H])([H])[H])O[H])O[H])=O)=O)C([H])(C([H])([H])[H])O[H])=O
|
| InChi Key |
NSFFHOGKXHRQEW-DVRIZHICSA-N
|
| InChi Code |
InChI=1S/C72H85N19O18S5/c1-14-26(3)47-63(105)78-30(7)57(99)75-28(5)56(98)76-31(8)58(100)91-72-19-18-40(66-85-43(22-111-66)59(101)77-29(6)55(97)74-27(4)54(73)96)81-52(72)42-21-112-67(83-42)49(34(11)109-69(107)41-20-37(32(9)92)36-16-17-39(79-47)51(95)50(36)80-41)89-60(102)44-24-113-68(86-44)53(71(13,108)35(12)94)90-62(104)45-23-110-65(84-45)38(15-2)82-64(106)48(33(10)93)88-61(103)46-25-114-70(72)87-46/h15-17,20-22,24-26,30-35,39,45,47-49,51-53,79,92-95,108H,4-6,14,18-19,23H2,1-3,7-13H3,(H2,73,96)(H,74,97)(H,75,99)(H,76,98)(H,77,101)(H,78,105)(H,82,106)(H,88,103)(H,89,102)(H,90,104)(H,91,100)/b38-15+
|
| Chemical Name |
N-[3-[(3-amino-3-oxoprop-1-en-2-yl)amino]-3-oxoprop-1-en-2-yl]-2-[(11Z)-37-butan-2-yl-18-(2,3-dihydroxybutan-2-yl)-11-ethylidene-59-hydroxy-8,31-bis(1-hydroxyethyl)-26,40,46-trimethyl-43-methylidene-6,9,16,23,28,38,41,44,47-nonaoxo-27-oxa-3,13,20,56-tetrathia-7,10,17,24,36,39,42,45,48,52,58,61,62,63,64-pentadecazanonacyclo[23.23.9.329,35.12,5.112,15.119,22.154,57.01,53.032,60]tetrahexaconta-2(64),4,12(63),19(62),21,29(61),30,32(60),33,51,54,57-dodecaen-51-yl]-1,3-thiazole-4-carboxamide
|
| Synonyms |
NSC-170365; NSC170365;NSC 170365;
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100~125 mg/mL ( 60.06~75.08 mM )
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (3.00 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 5 mg/mL (3.00 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 4.17 mg/mL (2.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5% DMSO+ 40% PEG300+ 5% Tween 80+ 50% ddH2O: 1.25mg/ml (0.75mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6006 mL | 3.0032 mL | 6.0064 mL | |
| 5 mM | 0.1201 mL | 0.6006 mL | 1.2013 mL | |
| 10 mM | 0.0601 mL | 0.3003 mL | 0.6006 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05278975 | RECRUITING | Drug: RSO-021 | Malignant Pleural Effusion Malignant Pleural Mesothelioma Mesothelioma Mesothelioma; Lung |
RS Oncology LLC | 2022-03-31 | Phase 1 Phase 2 |
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
